This clinical-stage biotech focused on cystic fibrosis therapies reported a notable insider sale amid a year of sharp ownership reductions.

Drug companies are starting 2026 by lifting list prices on a huge slate of brand name medicines, even as the White House and ...

If 2025 was the year AI got a vibe check, 2026 will be the year the tech gets practical. The focus is already shifting away from ...